

Karl Haslam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7201547/publications.pdf>

Version: 2024-02-01

29
papers

240
citations

1307594

7
h-index

996975

15
g-index

29
all docs

29
docs citations

29
times ranked

499
citing authors

#	ARTICLE	IF	CITATIONS
1	International external quality assurance of JAK2 V617F quantification. <i>Annals of Hematology</i> , 2019, 98, 1111-1118.	1.8	3
2	Neutrophilia and the JAK2 V617F Mutation. <i>Pathology and Oncology Research</i> , 2019, 25, 437-438.	1.9	0
3	Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 98-103.	0.7	6
4	An acquired <i>NRAS</i> mutation contributes to neutrophilic progression in a patient with primary myelofibrosis. <i>British Journal of Haematology</i> , 2018, 183, 308-310.	2.5	3
5	Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2018, 2018, 1-4.	0.4	0
6	Who to screen for calreticulin mutations? An audit of real-life practice and review of current evidence. <i>European Journal of Internal Medicine</i> , 2017, 40, e22-e23.	2.2	3
7	A novel molecular assay using hybridisation probes and melt curve analysis for CALR R453Q mutation detection in myeloproliferative neoplasms. <i>Journal of Clinical Pathology</i> , 2017, 70, 662-668.	2.0	2
8	The mutant CALR allele burden in essential thrombocythemia at transformation to acute myeloid leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 65, 66-67.	1.4	1
9	Isolated erythrocytosis associated with a CALR mutation. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 66, 6-7.	1.4	4
10	Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 85-88.	0.9	3
11	The JAK2 V617F mutation and thrombocytopenia. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 44-45.	0.9	3
12	Chronic Myeloid Leukemia with an e6a2BCR-ABL1 Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring. <i>Case Reports in Hematology</i> , 2017, 2017, 1-5.	0.4	2
13	Molecular Investigation of a Suspected Myeloproliferative Neoplasm in Patients with Basophilia. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, EL01.	0.8	2
14	Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia. <i>Case Reports in Hematology</i> , 2016, 2016, 1-5.	0.4	3
15	Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches. <i>BioMed Research International</i> , 2016, 2016, 1-6.	1.9	8
16	CALR mutation profile in Irish patients with myeloproliferative neoplasms. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 112-115.	0.9	0
17	Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 161-163.	2.5	18
18	Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 457-461.	3.8	9

#	ARTICLE	IF	CITATIONS
19	Capricious CALR mutated clones in myeloproliferative neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 57, 110-111.	1.4	1
20	The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis. <i>Pathology and Oncology Research</i> , 2016, 22, 229-230.	1.9	2
21	Molecular diagnostics of myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2015, 95, 270-279.	2.2	67
22	Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation. <i>Case Reports in Hematology</i> , 2015, 2015, 1-4.	0.4	1
23	Incidence of CALR mutations in patients with splanchnic vein thrombosis. <i>British Journal of Haematology</i> , 2015, 168, 459-460.	2.5	36
24	Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2014, 166, 800-802.	2.5	30
25	Monitoring Residual Disease in the Ph-Negative Myeloproliferative Neoplasms Post-Allogeneic Stem Cell Transplantation: More Mutations and More Methodologies. <i>Frontiers in Oncology</i> , 2014, 4, 212.	2.8	4
26	Considerations and Recommendations for a New Molecular Diagnostic Algorithm for the Myeloproliferative Neoplasms. <i>Genetic Testing and Molecular Biomarkers</i> , 2014, 18, 749-753.	0.7	1
27	Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, e29-31.	2.3	7
28	The molecular landscape of childhood myeloproliferative neoplasms. <i>Leukemia Research</i> , 2014, 38, 997-998.	0.8	4
29	Allogeneic Hematopoietic Stem Cell Transplantation for aBCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia. <i>Case Reports in Hematology</i> , 2012, 2012, 1-5.	0.4	17